Former Surgeon General Calls for Clinician-Guided FDA Framework on Peptides

Jerome Adams, former U.S. Surgeon General, published an opinion in STAT News arguing that the FDA should regulate the growing peptide market through a structured framework that centers clinician oversight. The piece comes amid a surge in direct-to-consumer peptide use, much of it operating in regulatory gray zones.

Why it matters

Jerome Adams is not a fringe voice, and that is exactly why this op-ed deserves a careful read rather than a reflexive nod. His core argument is that the peptide market has outpaced regulatory infrastructure, and that the FDA needs a framework built around clinical judgment rather than blanket prohibition or continued neglect. That framing is reasonable. The current situation, where patients are sourcing BPC-157 and tirzepatide analogs from compounding pharmacies or overseas suppliers with minimal oversight, is genuinely problematic for patient safety and for clinicians trying to practice responsibly.

The harder question is what a clinician-guided framework actually looks like in practice. Peptides span a wide spectrum of evidence quality, risk profiles, and use cases. Some have legitimate research behind them; many do not. Placing clinicians at the center of oversight only works if those clinicians have access to reliable data, clear liability guidance, and institutional support. Without those foundations, you are not creating a safety net. You are just shifting responsibility onto individual practitioners who are already navigating incomplete information. The policy conversation needs to get more specific before it gets more optimistic.

What to watch

Whether the FDA responds with concrete rulemaking or lets this remain an opinion piece that gathers citations but no action.